株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のスポーツ医学医師調査

Global Sports Medicine Physician Survey - 2014

発行 iData Research Inc. 商品コード 333127
出版日 ページ情報 英文 318 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。

ご注意: Single Userライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
認証されたPC上のみでの閲覧となっております。

Back to Top
世界のスポーツ医学医師調査 Global Sports Medicine Physician Survey - 2014
出版日: 2015年01月01日 ページ情報: 英文 318 Pages
概要

当レポートでは、世界のスポーツ医学に携わる医師への調査を実施し、ヒアルロン酸関節内補充療法(HAV)、濃縮骨髄穿刺液(cBMA)、多血小板血漿(PPP)製品に対するエンドユーザーの意見と認識についてまとめています。回答は、米国をはじめとする各国の整形外科医200余名から集められました。

第1章 調査方法

第2章 米国

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第3章 カナダ

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第4章 英国

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第5章 アルゼンチン

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第6章 ブラジル

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第7章 コロンビア

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第8章 ベネズエラ

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第9章 メキシコ

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第10章 ドミニカ共和国

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第11章 ヨルダン

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第12章 インド

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第13章 北米

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第14章 南米

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第15章 中米・カリブ海諸国

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第16章 西欧

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第17章 東欧

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第18章 中東

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第19章 アフリカ

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)

第20章 アジア

  • ヒアルロン酸関節内補充療法(HAV)
  • 多血小板血漿(PPP)および濃縮骨髄穿刺液(cBMA)
目次
Product Code: iDATA_GLBSMPS14_RPT

iData's Global Physician Surveys are conducted by highly trained moderators with years of experience in applying iData's rigorous methodology to ensure balanced responses and to elicit keen insight from physicians, surgeons, specialists and other medical professionals. iData's Global Physician Surveys are used to garner brand awareness, product preferences, message feedback and positioning.

iData's Physician Surveys allow the inclusion of a diverse range of medical professionals in broader geographical areas. They also eliminate group bias and allow for interactive one-on-one feedback as well as flexibility to expose the respondent to interactive or static media.

The ‘Global Sports Medicine Physician Survey’ report is a global survey regarding end-user attitudes and perceptions towards Hyaluronic Acid Viscosupplementation (HAV), Concentrated Bone Marrow Aspirate (cBMA) and Platelet-Rich Plasma (PRP) products. Responses from over 200 orthopedic surgeons from the United States and several other countries were gathered in person at the annual meeting of the American Academy of Orthopedic Surgeons.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

RESEARCH METHODOLOGY

  • 1.1. RESEARCH OVERVIEW
  • 1.2. RESEARCH SERVICES
  • 1.3. SURVEY METHODOLOGY

UNITED STATES

  • 2.1. U.S. HYALURONIC ACID VISCOSUPPLEMENTATION
    • 2.1.1. Physician Average Years of Practice in the U.S.
    • 2.1.2. Clinical Settings in the U.S.
    • 2.1.3. HA Viscosupplementation Brands in the U.S.
    • 2.1.4. HA Viscosupplementation Injection Trends in the U.S.
    • 2.1.5. HA Viscosupplementation Brand Purchasing Trends in the U.S.
    • 2.1.6. Brand Adoption Trends in the U.S.
    • 2.1.7. Purchasing Channel Trends in the U.S.
  • 2.2. U.S. PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 2.2.1. PRP & cBMA Usage in the U.S.
    • 2.2.2. cBMA Brands in the U.S.
    • 2.2.3. PRP Brands in the U.S.
    • 2.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, U.S.

CANADA

  • 3.1. CANADA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 3.1.1. Physician Average Years of Practice in Canada
    • 3.1.2. Clinical Settings of Respondents in Canada
    • 3.1.3. HA Viscosupplementation Brands in Canada
    • 3.1.4. HA Viscosupplementation Injection Trends in Canada
    • 3.1.5. HA Viscosupplementation Brand Purchasing Trends in Canada
    • 3.1.6. Brand Adoption Trends in Canada
    • 3.1.7. Purchasing Channel Trends in Canada
  • 3.2. CANADA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 3.2.1. PRP & cBMA Usage in Canada
    • 3.2.2. cBMA & PRP Brands in Canada
    • 3.2.3. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Canada

UNITED KINGDOM

  • 4.1. U.K. HYALURONIC ACID VISCOSUPPLEMENTATION
    • 4.1.1. Physician Average Years of Practice in the U.K.
    • 4.1.2. Clinical Settings in the U.K.
    • 4.1.3. HA Viscosupplementation Brands in the U.K.
    • 4.1.4. HA Viscosupplementation Injection Trends in the U.K.
    • 4.1.5. HA Viscosupplementation Brand Purchasing Trends in the U.K.
    • 4.1.6. Brand Adoption Trends in the U.K.
    • 4.1.7. Purchasing Channel Trends in the U.K.
  • 4.2. U.K. PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 4.2.1. PRP & cBMA Usage in the U.K.
    • 4.2.2. cBMA & PRP Brands in the U.K.
    • 4.2.3. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, U.K.

ARGENTINA

  • 5.1. ARGENTINA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 5.1.1. Physician Average Years of Practice in Argentina
    • 5.1.2. Clinical Settings in Argentina
    • 5.1.3. HA Viscosupplementation Brands in Argentina
    • 5.1.4. HA Viscosupplementation Injection Trends in Argentina
    • 5.1.5. HA Viscosupplementation Brand Purchasing Trends in Argentina
    • 5.1.6. Brand Adoption Trends in Argentina
    • 5.1.7. Purchasing Channel Trends in Argentina
  • 5.2. ARGENTINA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 5.2.1. PRP & cBMA Usage in Argentina
    • 5.2.2. cBMA Brands in Argentina
    • 5.2.3. PRP Brands in Argentina
    • 5.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Argentina

BRAZIL

  • 6.1. BRAZIL HYALURONIC ACID VISCOSUPPLEMENTATION
    • 6.1.1. Physician Average Years of Practice in Brazil
    • 6.1.2. Clinical Settings in Brazil
    • 6.1.3. HA Viscosupplementation Brands in Brazil
    • 6.1.4. HA Viscosupplementation Injection Trends in Brazil
    • 6.1.5. HA Viscosupplementation Brand Purchasing Trends in Brazil
    • 6.1.6. Brand Adoption Trends in Brazil
    • 6.1.7. Purchasing Channel Trends in Brazil
  • 6.2. BRAZIL PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 6.2.1. PRP & cBMA Usage in Brazil
    • 6.2.2. cBMA Brands in Brazil
    • 6.2.3. PRP Brands in Brazil
    • 6.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Brazil

COLOMBIA

  • 7.1. COLOUMBIA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 7.1.1. Physician Average Years of Practice in Colombia
    • 7.1.2. Clinical Settings in Colombia
    • 7.1.3. HA Viscosupplementation Brands in Colombia
    • 7.1.4. HA Viscosupplementation Injection Trends in Colombia
    • 7.1.5. HA Viscosupplementation Brand Purchasing Trends in Colombia
    • 7.1.6. Brand Adoption Trends in Colombia
    • 7.1.7. Purchasing Channel Trends in Colombia
  • 7.2. COLOMBIA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 7.2.1. PRP & cBMA Usage in Colombia
    • 7.2.2. cBMA Brands in Colombia
    • 7.2.3. PRP Brands in Colombia
    • 7.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Colombia

VENEZUELA

  • 8.1. VENEZUELA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 8.1.1. Physician Average Years of Practice in Venezuela
    • 8.1.2. Clinical Settings in Venezuela
    • 8.1.3. HA Viscosupplementation Brands in Venezuela
    • 8.1.4. HA Viscosupplementation Injection Trends in Venezuela
    • 8.1.5. HA Viscosupplementation Brand Purchasing Trends in Venezuela
    • 8.1.6. Brand Adoption Trends in Venezuela
    • 8.1.7. Purchasing Channel Trends in Venezuela
  • 8.2. VENEZUELA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 8.2.1. PRP & cBMA Usage in Venezuela
    • 8.2.2. cBMA Brands in Venezuela
    • 8.2.3. PRP Brands in Venezuela
    • 8.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Venezuela

MEXICO

  • 9.1. MEXICO HYALURONIC ACID VISCOSUPPLEMENTATION
    • 9.1.1. Physician Average Years of Practice in Mexico
    • 9.1.2. Clinical Settings in Mexico
    • 9.1.3. HA Viscosupplementation Brands in Mexico
    • 9.1.4. HA Viscosupplementation Injection Trends in Mexico
    • 9.1.5. HA Viscosupplementation Brand Purchasing Trends in Mexico
    • 9.1.6. Brand Adoption Trends in Mexico
    • 9.1.7. Purchasing Channel Trends in Mexico
  • 9.2. MEXICO PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 9.2.1. PRP & cBMA Usage in Mexico
    • 9.2.2. cBMA Brands in Mexico
    • 9.2.3. PRP Brands in Mexico
    • 9.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Mexico

DOMINICAN REPUBLIC

  • 10.1. DOMINICAN REPUBLIC HYALURONIC ACID VISCOSUPPLEMENTATION
    • 10.1.1. Physician Average Years of Practice in Dominican Republic
    • 10.1.2. Clinical Settings in Dominican Republic
    • 10.1.3. HA Viscosupplementation Brands in Dominican Republic
    • 10.1.4. HA Viscosupplementation Injection Trends in Dominican Republic
    • 10.1.5. HA Viscosupplementation Brand Purchasing Trends in Dominican Republic
    • 10.1.6. Brand Adoption Trends in Dominican Republic
    • 10.1.7. Purchasing Channel Trends in Dominican Republic
  • 10.2. DOMINICAN REPUBLIC PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 10.2.1. PRP & cBMA Usage in Dominican Republic
    • 10.2.2. cBMA Brands in Dominican Republic
    • 10.2.3. PRP Brands in Dominican Republic
    • 10.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Dominican Republic

JORDAN

  • 11.1. JORDAN HYALURONIC ACID VISCOSUPPLEMENTATION
    • 11.1.1. Physician Average Years of Practice in Jordan
    • 11.1.2. Clinical Settings in Jordan
    • 11.1.3. HA Viscosupplementation Brands in Jordan
    • 11.1.4. HA Viscosupplementation Injection Trends in Jordan
    • 11.1.5. HA Viscosupplementation Brand Purchasing Trends in Jordan
    • 11.1.6. Brand Adoption Trends in Jordan
    • 11.1.7. Purchasing Channel Trends in Jordan
  • 11.2. JORDAN PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 11.2.1. PRP & cBMA Usage in Jordan
    • 11.2.2. cBMA Brands in Jordan
    • 11.2.3. PRP Brands in Jordan
    • 11.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Jordan

INDIA

  • 12.1. INDIA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 12.1.1. Physician Average Years of Practice in India
    • 12.1.2. Clinical Settings in India
    • 12.1.3. HA Viscosupplementation Brands in India
    • 12.1.4. HA Viscosupplementation Injection Trends in India
    • 12.1.5. HA Viscosupplementation Brand Purchasing Trends in India
    • 12.1.6. Brand Adoption Trends in India
    • 12.1.7. Purchasing Channel Trends in India
  • 12.2. INDIA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 12.2.1. PRP & cBMA Usage in India
    • 12.2.2. cBMA Brands in India
    • 12.2.3. PRP Brands in India
    • 12.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, India

NORTH AMERICA

  • 13.1. NORTH AMERICA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 13.1.1. Physician Average Years of Practice in North America
    • 13.1.2. Clinical Settings in North America
    • 13.1.3. HA Viscosupplementation Brands in North America
    • 13.1.4. HA Viscosupplementation Injection Trends in North America
    • 13.1.5. HA Viscosupplementation Brand Purchasing Trends in North America
    • 13.1.6. Brand Adoption Trends in North America
    • 13.1.7. Purchasing Channel Trends in North America
  • 13.2. NORTH AMERICA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 13.2.1. PRP & cBMA Usage in North America
    • 13.2.2. cBMA Brands in North America
    • 13.2.3. PRP Brands in North America
    • 13.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, North America

SOUTH AMERICA

  • 14.1. SOUTH AMERICA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 14.1.1. Physician Average Years of Practice in South America
    • 14.1.2. Clinical Settings in South America
    • 14.1.3. HA Viscosupplementation Brands in South America
    • 14.1.4. HA Viscosupplementation Injection Trends in South America
    • 14.1.5. HA Viscosupplementation Brand Purchasing Trends in South America
    • 14.1.6. Brand Adoption Trends in South America
    • 14.1.7. Purchasing Channel Trends in South America
  • 14.2. SOUTH AMERICA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 14.2.1. PRP & cBMA Usage in South America
    • 14.2.2. cBMA Brands in South America
    • 14.2.3. PRP Brands in South America
    • 14.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, South America

CENTRAL AMERICA & THE CARRIBEAN

  • 15.1. SOUTH AMERICA & THE CARIBBEAN HYALURONIC ACID VISCOSUPPLEMENTATION
    • 15.1.1. Physician Average Years of Practice in Central America & the Caribbean
    • 15.1.2. Clinical Settings in Central America & the Caribbean
    • 15.1.3. HA Viscosupplementation Brands in Central America & the Caribbean
    • 15.1.4. HA Viscosupplementation Injection Trends in Central America & the Caribbean
    • 15.1.5. HA Viscosupplementation Brand Purchasing Trends in Central America & the Caribbean
    • 15.1.6. Brand Adoption Trends in Central America & the Caribbean
    • 15.1.7. Purchasing Channel Trends in Central America & the Caribbean
  • 15.2. CENTRAL AMERICA & THE CARIBBEAN PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 15.2.1. PRP & cBMA Usage in Central America & the Caribbean
    • 15.2.2. cBMA Brands in Central America & the Caribbean
    • 15.2.3. PRP Brands in Central America & the Caribbean
    • 15.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Central America & the Caribbean

WESTERN EUROPE

  • 16.1. WESTERN EUROPE HYALURONIC ACID VISCOSUPPLEMENTATION
    • 16.1.1. Physician Average Years of Practice in Western Europe
    • 16.1.2. Clinical Settings in Western Europe
    • 16.1.3. HA Viscosupplementation Brands in Western Europe
    • 16.1.4. HA Viscosupplementation Injection Trends in Western Europe
    • 16.1.5. HA Viscosupplementation Brand Purchasing Trends in Western Europe
    • 16.1.6. Brand Adoption Trends in Western Europe
    • 16.1.7. Purchasing Channel Trends in Western Europe
  • 16.2. WESTERN EUROPE PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 16.2.1. PRP & cBMA Usage in Western Europe
    • 16.2.2. cBMA Brands in Western Europe
    • 16.2.3. PRP Brands in Western Europe
    • 16.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Western Europe

EASTERN EUROPE

  • 17.1. EASTERN EUROPE HYALURONIC ACID VISCOSUPPLEMENTATION
    • 17.1.1. Physician Average Years of Practice in Eastern Europe
    • 17.1.2. Clinical Settings in Eastern Europe
    • 17.1.3. HA Viscosupplementation Brands in Eastern Europe
    • 17.1.4. HA Viscosupplementation Injection Trends in Eastern Europe
    • 17.1.5. HA Viscosupplementation Brand Purchasing Trends in Eastern Europe
    • 17.1.6. Brand Adoption Trends in Eastern Europe
    • 17.1.7. Purchasing Channel Trends in Eastern Europe
  • 17.2. EASTERN EUROPE PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 17.2.1. PRP & cBMA Usage in Eastern Europe
    • 17.2.2. cBMA Brands in Eastern Europe
    • 17.2.3. PRP Brands in Eastern Europe
    • 17.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Eastern Europe

MIDDLE EAST

  • 18.1. MIDDLE EAST HYALURONIC ACID VISCOSUPPLEMENTATION
    • 18.1.1. Physician Average Years of Practice in the Middle East
    • 18.1.2. Clinical Settings in the Middle East
    • 18.1.3. HA Viscosupplementation Brands in the Middle East
    • 18.1.4. HA Viscosupplementation Injection Trends in the Middle East
    • 18.1.5. HA Viscosupplementation Brand Purchasing Trends in the Middle East
    • 18.1.6. Brand Adoption Trends in the Middle East
    • 18.1.7. Purchasing Channel Trends in the Middle East
  • 18.2. MIDDLE EAST PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 18.2.1. PRP & cBMA Usage in the Middle East
    • 18.2.2. cBMA Brands in the Middle East
    • 18.2.3. PRP Brands in the Middle East
    • 18.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Middle East

AFRICA

  • 19.1. AFRICA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 19.1.1. Physician Average Years of Practice in Africa
    • 19.1.2. Clinical Settings in Africa
    • 19.1.3. HA Viscosupplementation Brands in Africa
    • 19.1.4. HA Viscosupplementation Injection Trends in Africa
    • 19.1.5. HA Viscosupplementation Brand Purchasing Trends in Africa
    • 19.1.6. Brand Adoption Trends in Africa
    • 19.1.7. Purchasing Channel Trends in Africa
  • 19.2. AFRICA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 19.2.1. PRP & cBMA Usage in Africa
    • 19.2.2. cBMA Brands in Africa
    • 19.2.3. PRP Brands in Africa
    • 19.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Africa

ASIA

  • 20.1. ASIA HYALURONIC ACID VISCOSUPPLEMENTATION
    • 20.1.1. Physician Average Years of Practice in Asia
    • 20.1.2. Clinical Settings in Asia
    • 20.1.3. HA Viscosupplementation Brands in Asia
    • 20.1.4. HA Viscosupplementation Injection Trends in Asia
    • 20.1.5. HA Viscosupplementation Brand Purchasing Trends in Asia
    • 20.1.6. Brand Adoption Trends in Asia
    • 20.1.7. Purchasing Channel Trends in Asia
  • 20.2. AFRICA PLATELET RICH PLASMA & CONCENTRATED BONE MARROW ASPIRATE
    • 20.2.1. PRP & cBMA Usage in Asia
    • 20.2.2. cBMA Brands in Asia
    • 20.2.3. PRP Brands in Asia
    • 20.2.4. PRP Usage for Tendonitis/Tendonosis & Osteoarthritis, Asia

APPENDIX

  • 21.1. SURVEY RESPONDENTS BY GEOGRAPHICAL DISTRIBUTION

ABBREVIATIONS

Back to Top